APT-101 demonstrates efficacy in model of lung injury and fibrosis
Aug. 5, 2022
Researchers from APIE Therapeutics presented preclinical data for the novel apelin receptor (APJ) agonist, APT-101, being developed as a small-molecule antifibrotic and anti-inflammatory agent.
